<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05022914</url>
  </required_header>
  <id_info>
    <org_study_id>PSICHE</org_study_id>
    <nct_id>NCT05022914</nct_id>
  </id_info>
  <brief_title>PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE</brief_title>
  <acronym>PSICHE</acronym>
  <official_title>Prostate-Specific Membrane Antigen (PSMA) Guided Approach for bIoCHEmical Relapse After Prostatectomy- A Prospective Observational Study-PSICHE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria Careggi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria Careggi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study was designed to evaluate progression free survival after PSMA-PET/CT&#xD;
      based salvage approach for patients affected by biochemical relapse after radical&#xD;
      prostatectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective observational multicenter study including patients treated with upfront&#xD;
      radical prostatectomy +/- postoperative prostate bed radiotherapy, with histological result&#xD;
      of Prostate adenocarcinoma, affected by biochemical relapse (defined as PSA&gt;/= 0.2 ng/ml)&#xD;
      with a PSA at recurrence &lt;/=1 ng/ml. Patients will be staged with centralized 68 Ga- PSMA&#xD;
      PET/CT and treated with a pre-defined approach based on 68 Ga-PSMA PET/CT findings.&#xD;
&#xD;
      The predefined approach will consist in the following flowchart:&#xD;
&#xD;
        1. In negative 68Ga-PSMA PET/CT or positive findings within prostate bed: Prostate bed RT&#xD;
&#xD;
        2. In 68Ga-PSMA PET/CT detecting pelvic nodal recurrence amenable with stereotactic body&#xD;
           radiation therapy (SBRT) on all sites of disease: SBRT to all positive nodal disease.&#xD;
&#xD;
        3. In abdominal nodal or bone oligometastatic disease amenable with stereotactic body&#xD;
           radiation therapy (SBRT) on all sites of disease: SBRT on all sites of disease&#xD;
&#xD;
        4. In abdominal nodal or bone metastatic disease (&gt;3 lesions or non-amenable with SBRT)&#xD;
           and/or visceral disease: ADT+/-other systemic therapies available for metastatic hormone&#xD;
           sensitive pCa at physician discretion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2021</start_date>
  <completion_date type="Anticipated">January 19, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 19, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 year</time_frame>
    <description>PFS is defined as time from end of salvage treatment performed at first relapse to documented biochemical progression or radiological progression (or both), death from any cause or censoring at date of last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time between end of tailored treatment after 68Ga-PSMA PET/CT and death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause-specific survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time between end of tailored treatment and death for prostate Cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>The occurrence of any new lesion detectable with PSMA. PET/CT and/or any other molecular/radiological exam, which will be performed in case of biochemical or clinical progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2 years</time_frame>
    <description>Record rate of patients with impaired quality of life measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2 years</time_frame>
    <description>Record rate of patients with impaired quality of life measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-PR25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Management Change</measure>
    <time_frame>2 years</time_frame>
    <description>Assess the proportion of management changes induced by positive PSMA PET/CT results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between PSMA PET/CT Detection Rate and specific miRNA panel</measure>
    <time_frame>2 year</time_frame>
    <description>Association between PSMA PET/CT Detection Rate and specific miRNA panel</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Biochemical Relapse Fo Malignant Neoplasm of Prostate</condition>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Prostate Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients affected by biochemical relapse after radical prostatectomy undergoing staging PSMA-PET/CT and baseline blood sample for miRNA panel assessment.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Panel of miRNA (miR-186, miR-26a, miR-374a, miR-410, miR-660)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient affected by biochemical recurrence after radical prostatectomy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Age &gt;18&#xD;
&#xD;
          -  Patient suitable for 68Ga-PSMA PET/CT re-staging according to clinical practice&#xD;
             (Previous radical prostatectomy with histological result of Prostate adenocarcinoma&#xD;
             +/- postoperative prostate bed radiotherapy (adjuvant or salvage setting), with a&#xD;
             biochemical relapse defined as a PSA &gt; 0.2 and &lt;1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ADT administration within 6 months from study enrollment&#xD;
&#xD;
          -  Persistent elevation of PSA after RP measured within 16 weeks from surgery (&gt; 0.1&#xD;
             ng/ml)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Prostate cancer male patient</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenzo Livi, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria Careggi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lorenzo Livi, Prof.</last_name>
    <phone>+390557947264</phone>
    <email>lorenzo.livi@unifi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>AOU Careggi Radiation Oncology Unit</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Livi, Prof.</last_name>
      <phone>+390557947264</phone>
      <email>segr-radiotp@dfc.unifi.it</email>
    </contact>
    <contact_backup>
      <last_name>Giulio Francolini</last_name>
      <phone>3938576664</phone>
      <email>Francolinigiulio@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.</citation>
    <PMID>27568654</PMID>
  </results_reference>
  <results_reference>
    <citation>Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf JS Jr, Faraday MM. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013 Aug;190(2):441-9. doi: 10.1016/j.juro.2013.05.032. Epub 2013 May 21.</citation>
    <PMID>23707439</PMID>
  </results_reference>
  <results_reference>
    <citation>Pisansky TM, Thompson IM, Valicenti RK, D'Amico AV, Selvarajah S. Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019. J Urol. 2019 Sep;202(3):533-538. doi: 10.1097/JU.0000000000000295. Epub 2019 Aug 8.</citation>
    <PMID>31042111</PMID>
  </results_reference>
  <results_reference>
    <citation>Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016 Oct 20;34(30):3648-3654. doi: 10.1200/JCO.2016.67.9647.</citation>
    <PMID>27528718</PMID>
  </results_reference>
  <results_reference>
    <citation>Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.</citation>
    <PMID>27591931</PMID>
  </results_reference>
  <results_reference>
    <citation>Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schäfer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268. doi: 10.1007/s00259-017-3711-7. Epub 2017 May 12. Erratum in: Eur J Nucl Med Mol Imaging. 2017 Sep;44(10 ):1781.</citation>
    <PMID>28497198</PMID>
  </results_reference>
  <results_reference>
    <citation>Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. Erratum in: Lancet Oncol. 2019 Nov;20(11):e613. Erratum in: Lancet Oncol. 2020 Jun;21(6):e304.</citation>
    <PMID>31375469</PMID>
  </results_reference>
  <results_reference>
    <citation>Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M 3rd, Briganti A. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015 May;67(5):852-63. doi: 10.1016/j.eururo.2014.09.004. Epub 2014 Sep 17. Review.</citation>
    <PMID>25240974</PMID>
  </results_reference>
  <results_reference>
    <citation>Deandreis D, Guarneri A, Ceci F, Lillaz B, Bartoncini S, Oderda M, Nicolotti DG, Pilati E, Passera R, Zitella A, Bellò M, Parise R, Carlevato R, Ricardi U, Gontero P. (68)Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2804-2815. doi: 10.1007/s00259-020-04809-8. Epub 2020 Apr 20.</citation>
    <PMID>32314028</PMID>
  </results_reference>
  <results_reference>
    <citation>Erdmann K, Kaulke K, Thomae C, Huebner D, Sergon M, Froehner M, Wirth MP, Fuessel S. Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs. BMC Cancer. 2014 Feb 11;14:82. doi: 10.1186/1471-2407-14-82.</citation>
    <PMID>24517338</PMID>
  </results_reference>
  <results_reference>
    <citation>D'Angelillo RM, Francolini G, Ingrosso G, Ravo V, Triggiani L, Magli A, Mazzeo E, Arcangeli S, Alongi F, Jereczek-Fossa BA, Pergolizzi S, Pappagallo GL, Magrini SM. Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO). Crit Rev Oncol Hematol. 2019 Jun;138:24-28. doi: 10.1016/j.critrevonc.2019.03.014. Epub 2019 Apr 1. Review.</citation>
    <PMID>31092381</PMID>
  </results_reference>
  <results_reference>
    <citation>Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, Supiot S, Belkacemi Y, Peiffert D, Allouache N, Dubray BM, Servagi-Vernat S, Suchaud JP, Crehange G, Guerif S, Brihoum M, Barbier N, Graff-Cailleaud P, Ruffion A, Dussart S, Ferlay C, Chabaud S. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019 Dec;20(12):1740-1749. doi: 10.1016/S1470-2045(19)30486-3. Epub 2019 Oct 16.</citation>
    <PMID>31629656</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria Careggi</investigator_affiliation>
    <investigator_full_name>Lorenzo Livi</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <keyword>PSMA</keyword>
  <keyword>68Ga-PSMA PET/CT</keyword>
  <keyword>PET/CT</keyword>
  <keyword>Biochemical Relapse</keyword>
  <keyword>micro-RNA</keyword>
  <keyword>SBRT</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

